Drug Interactions between glycerol phenylbutyrate and Oncovin

MONITOR: Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo. In healthy subjects, coadministration of glycerol phenylbutyrate (4.4 g orally three times daily for 3 days) with oral midazolam, a sensitive CYP450 3A4 substrate, decreased the peak plasma concentration (Cmax) and systemic exposure (AUC) of midazolam of approximately 25% and 32%, respectively, and increased the mean Cmax and AUC of its metabolite 1-hydroxy midazolam, by 28% and 58%, respectively, compared to administration of midazolam alone. The clinical significance has not been established.

MANAGEMENT: Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.

Switch to consumer interaction data